Market Analysis and Insights: Global Brain Tumor Therapeutics Market
A brain tumor occurs when abnormal cells form within the brain.
The global Brain Tumor Therapeutics market size is projected to reach US$ 2298.4 million by 2028, from US$ 1112.4 million in 2021, at a CAGR of 10.4% during 2022-2028.
North America dominates the brain tumor therapeutics market due to increasing technological advancements and the rising incidences of brain cancer in the country. Asia-Pacific is also expected to propel the brain tumor therapeutics market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing geriatric population.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Brain Tumor Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Brain Tumor Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Brain Tumor Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Brain Tumor Therapeutics market.
Global Brain Tumor Therapeutics Scope and Market Size
Brain Tumor Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Brain Tumor Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Surgery
Radiation Therapy
Targeted Therapy
Chemotherapy
Immunotherapy
Segment by Application
Hospitals
Oncology Treatment Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Novartis
Roche
Merck
AstraZeneca
GE Healthcare
Hitachi Medical
Philips Healthcare
Novocure
DelMar Pharmaceuticals